Allison Barz Leahy, MD MSCE
Assistant Professor of Pediatrics (Oncology) at the Children's Hospital of Philadelphia
Core Faculty, Clinical Futures, Children's Hospital of Philadelphia
Innovation Faculty Member, Penn Center for Cancer Care Innovation, University of Pennsylvania
Department: Pediatrics
Contact information
Children's Hospital of Philadelphia
HUB For Clinical Collaboration
3500 Civic Center Boulevard
Philadelphia, PA 19104
HUB For Clinical Collaboration
3500 Civic Center Boulevard
Philadelphia, PA 19104
Office: 267-253-8133
Email:
barza@chop.edu
barza@chop.edu
Education:
BA (Russian Language Major, Chemistry Minor)
Bowdoin College , 2005.
MA (Biological Sciences)
Hunter College of the City of New York, 2008.
MD
SUNY Upstate Medical University, 2012.
MSCE
University of Pennsylvania, 2020.
Permanent linkBA (Russian Language Major, Chemistry Minor)
Bowdoin College , 2005.
MA (Biological Sciences)
Hunter College of the City of New York, 2008.
MD
SUNY Upstate Medical University, 2012.
MSCE
University of Pennsylvania, 2020.
Description of Clinical Expertise
Patient-reported outcomes (PROs), relapsed and refractory leukemia, CAR T cellsDescription of Research Expertise
Patient-reported outcomes (PROs), pediatric health outcomes, phase 1 clinical trials, relapsed and refractory leukemia, pediatric oncologySelected Publications
Zheng DJ, Wang L, Getz K, Aplenc R, Coughlin KQ, DiNofia AM, Maude SL, Myers RM, Newman H, Orsini T, Paris D, Grupp SA, Leahy AB: Financial toxicity and association with treatment outcomes during pediatric CAR T therapy. ASCO May 2025.Leahy AB: IKAROS facilitates antigen escape in the face of CD19- and CD22-targeted therapies for B-cell malignancies. under review at Nature Communications Feb 2025.
Steineck A, Chao K, Hall AG, Jacoby E, Leahy AB, Ligon JA, Luciani K, Schultz LM, Summer CN, Ward L, Winestone LE, Shah NN: Access to CARe: A Narrative of Real-World Medical Decision-Making to Access Chimeric Antigen Receptor (CAR) T-Cell Therapy in Children, Adolescents, and Young Adults. Pediatric Blood and Cancer(e31516), Jan 2025.
Thorton C, Daniali M, Wang L, Makeneni S, Leahy AB : Using natural language processing to identify symptomatic adverse events in pediatric oncology: Tutorial for clinician researchers. JMIR Under Review 2025.
Friedes BD, DiNofia AM, Iannone E, Li Y, Rheingold SR, Barz Leahy A, Wray L, Callahan C, Baniewicz D, Vernau L, Getz KD, Aplenc R, Maude SL, Grupp SA, Myers RM.: Therapies and outcomes following extramedullary relapse of pediatric and young adult ALL after CD19 CAR T-cell therapy. Blood Adv Nov 2024.
Leahy AB, Brogdon J, Cain L, Dinofia AM, Fraietta JA, Hanna R, Kadauke S, Khan R, Li Y, Maude SL, Myers RM, Shinehouse L, Sparrow A, Varghese M, Wang L, Wang Y, Grupp SA: Cost-Effective Manufacture and Promising Initial Efficacy of huCART19 Cells Manufactured Using the Clinimacs Prodigy Platform. Blood 144: 3470, Nov 2024.
Basch E, Leahy AB, Reeve BB: Symptom Monitoring With Patient-Reported Outcomes During Pediatric Cancer Care JAMA 332(23): 1979-1980, Nov 2024.
Barz-Leahy A, Wang L, Paris D, Coughlin K, Orsini T, Myers R, Dinofia A, Maude SL, Grupp SA, Bekelman J, Feudtner C : PROs in pediatric immunotherapy: Longitudinal self- and proxy-reported symptoms in children treated with CAR T cells for advanced leukemia. ISOQOL, Cologne, Germany Oct 2024.
Newman H, Li Y, Huang YSV, Elgarten CW, Myers RM, Ruiz J, Zheng DJ, Barz Leahy A, Aftandilian C, Arnold SD, Bona K, Gramatges MM, Heneghan MB, Maloney KW, Modi AJ, Mody RJ, Morgan E, Rubnitz J, Winick N, Wilkes JJ, Seif AE, Fisher BT, Aplenc R, Getz KD: Household income and health-related quality of life in children receiving treatment for acute myeloid leukemia: Potential impact of selection bias in health equity research. Cancer Med. Apr 2024.
Myers RM, Devine KJ, Li Y, Lawrence S, Barz Leahy A, Liu H, Vernau L, Callahan C, Baniewicz D, Kadauke S, McGuire R, Wertheim G, Kulikovskaya I, Gonzalez V, Fraietta JA, DiNofia A, Hunger SP, Rheingold SR, Aplenc R, June CH, Grupp SA, Wray L, Maude SL.: Reinfusion of CD19 CAR T Cells for Relapse Prevention and Treatment in Children with Acute Lymphoblastic Leukemia. Blood Adv Feb 2024.